Published in Diabetes on March 01, 2003
Protein quality control in the early secretory pathway. EMBO J (2008) 3.59
A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst (2012) 1.74
Functions of AMP-activated protein kinase in adipose tissue. J Physiol (2006) 1.70
Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes (2009) 1.59
A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem (2009) 1.41
Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab (2008) 1.33
Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. Diabetes (2013) 1.08
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab (2008) 1.01
Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte (2013) 1.01
Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes (2012) 1.00
Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications. Am J Infect Dis (2006) 1.00
AMP-activated protein kinase and metabolic control. Handb Exp Pharmacol (2011) 0.99
No effect of metformin on the innate airway hyperresponsiveness and increased responses to ozone observed in obese mice. J Appl Physiol (1985) (2008) 0.98
Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis (2011) 0.97
Maternal serum adiponectin multimers in preeclampsia. J Perinat Med (2009) 0.92
Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. J Perinat Med (2007) 0.92
AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia (2011) 0.92
Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol (2011) 0.91
Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab (2009) 0.90
Adiponectin multimers in maternal plasma. J Matern Fetal Neonatal Med (2008) 0.89
Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int J Med Sci (2016) 0.88
Adiponectin: an adipokine with protective features against metabolic syndrome. Iran J Basic Med Sci (2015) 0.87
Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance. Am J Physiol Endocrinol Metab (2014) 0.85
Antidiabetic treatment restores adiponectin serum levels and APPL1 expression, but does not improve adiponectin-induced vasodilation and endothelial dysfunction in Zucker diabetic fatty rats. Cardiovasc Diabetol (2013) 0.83
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS (2011) 0.82
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents. J Obes (2015) 0.81
Deletion of AMPKα1 attenuates the anticontractile effect of perivascular adipose tissue (PVAT) and reduces adiponectin release. Br J Pharmacol (2016) 0.81
Metformin increases plasma ghrelin in Type 2 diabetes. Br J Clin Pharmacol (2009) 0.80
AMPK activation--protean potential for boosting healthspan. Age (Dordr) (2013) 0.78
Prorenin/renin receptor blockade promotes a healthy fat distribution in obese mice. Obesity (Silver Spring) (2016) 0.76
The impact of obesity and adiponectin signaling in patients with renal cell carcinoma: A potential mechanism for the "obesity paradox". PLoS One (2017) 0.75
Potential role of marine algae extract on 3T3-L1 cell proliferation and differentiation: an in vitro approach. Biol Res (2016) 0.75
A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy. Can J Kidney Health Dis (2016) 0.75
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov (2010) 4.22
Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes (2010) 3.77
Adiponectin: more than just another fat cell hormone? Diabetes Care (2003) 3.30
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Fat redistribution and adipocyte transformation in uninephrectomized rats. Kidney Int (2008) 2.18
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 2.17
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther (2008) 1.95
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature (2012) 1.85
Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care (2003) 1.85
Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med (2008) 1.69
Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care (2006) 1.68
Adiponectin in health and disease. Diabetes Obes Metab (2007) 1.64
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril (2007) 1.63
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes (2003) 1.62
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther (2012) 1.51
Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ (2008) 1.45
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes (2002) 1.44
Drug-induced endocrine and metabolic disorders. Drug Saf (2007) 1.42
Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care (2007) 1.34
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest (2011) 1.33
Thiazolidinedione safety. Expert Opin Drug Saf (2012) 1.33
Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol (2007) 1.32
Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care (2008) 1.32
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab (2013) 1.30
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract (2003) 1.26
Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care (2010) 1.23
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc (2003) 1.22
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Risk factors in V-shaped risk associations with all-cause mortality in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Metab Res Rev (2008) 1.20
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther (2013) 1.17
Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am J Physiol Endocrinol Metab (2007) 1.17
Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord (2009) 1.15
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes (2002) 1.15
Yoga for veterans with chronic low-back pain. J Altern Complement Med (2008) 1.15
Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care (2009) 1.13
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab (2008) 1.13
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab (2007) 1.11
Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer (2008) 1.10
Electron paramagnetic spectroscopic evidence of exercise-induced free radical accumulation in human skeletal muscle. Free Radic Res (2007) 1.08
Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci (2011) 1.08
Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab (2005) 1.07
Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol (2010) 1.07
BMI and waist circumference in predicting cardiovascular risk factor clustering in Chinese adolescents. Obesity (Silver Spring) (2007) 1.06
Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes (2002) 1.06
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med (2010) 1.06
Use of anti-diabetic drugs and glycaemic control in type 2 diabetes-tThe Hong Kong Diabetes Registry. Diabetes Res Clin Pract (2008) 1.06
Early response to preventive strategies in the Diabetes Prevention Program. J Gen Intern Med (2013) 1.06
Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in chinese patients with type 2 diabetes. Diabetes Care (2006) 1.06
Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes Res (2005) 1.04
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care (2002) 1.03
Relationship of sleep quantity and quality with 24-hour urinary catecholamines and salivary awakening cortisol in healthy middle-aged adults. Sleep (2011) 1.03
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care (2003) 1.03
Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes Registry. Diabetes Care (2008) 1.02
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract (2013) 1.02
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care (2013) 1.01
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab (2008) 1.01
Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte (2013) 1.01
Overweight, family history of diabetes and attending schools of lower academic grading are independent predictors for metabolic syndrome in Hong Kong Chinese adolescents. Arch Dis Child (2006) 1.01
Association between obesity and atopy in Chinese schoolchildren. Int Arch Allergy Immunol (2009) 1.00
Sedentary aging increases resting and exercise-induced intramuscular free radical formation. J Appl Physiol (1985) (2010) 0.99
Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes (2009) 0.99
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev (2006) 0.98
Diabetes-related distress and physical and psychological health in chinese type 2 diabetic patients. Diabetes Care (2011) 0.98
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol (2004) 0.98
Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep (2002) 0.98
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes (2013) 0.97
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab (2006) 0.97